p53

Investment decisions rest with co-founder Susanne Stuffers, supported by TD Veen's CIO Øyvind Schanke. Stuffers, an M.D. and Ph.D. with clinical oncology experience and sell-side equity research background, leads scientific and commercial due diligence. TD Veen's CEO Kjell Skappel and chair Silje Veen govern the overall capital allocation.

Proprietary sourcing draws on the team's deep Scandinavian academic and clinical networks, particularly through Oslo's Radiumhospital, where multiple team members studied or researched. Deal flow also comes from relationships with European life-science VCs like Forbion and Sunstone, and from management teams' direct outreach to a concentrated capital source.

It operates as the dedicated healthcare investment arm of family-owned TD Veen, deploying the family's balance sheet directly. It is not a third-party fund manager; all investments are made in line with TD Veen's overall strategy, giving it a single-family-office funding backbone while functioning as a specialized venture and growth equity investor.

p53 invests across preclinical and clinical stages. The portfolio includes preclinical platform companies like Valink Therapeutics, clinical-stage biotechs like Calluna Pharma, and later-stage public companies such as Nykode Therapeutics, reflecting a flexible mandate across the development timeline.

p53 is exclusively focused on healthcare and life sciences. It does not invest in software, consumer, industrials, or any sector outside biotechnology, pharmaceuticals, and healthcare innovation, in line with its mandate as TD Veen's sole healthcare-dedicated vehicle.

p53 was founded in 2018 as a subsidiary of TD Veen, the Stavanger-based family investment company. All p53 investments align with TD Veen's strategy and objectives. TD Veen's senior leadership — Kjell Skappel, Silje Veen, and Øyvind Schanke — are integral to p53's governance and investment processes.

p53 executes direct equity investments in private and public healthcare companies. It does not disclose commitments to third-party funds. Its model centers on active, direct ownership with board engagement, often alongside co-investors it selects for strategic alignment.